This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU
by Zacks Equity Research
Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.
Small-Cap ETF (VTWO) Hits New 52-Week High
by Sweta Killa
This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?
Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Schlumberger (SLB) Up 11.3% in a Day: What's Behind the Rally?
by Nilanjan Banerjee
Improving fuel demand on positive coronavirus vaccine results aids Schlumberger (SLB).
Dow ETF Hits New Highs on Vaccine Optimism: 5 Best Stocks
by Sweta Killa
The Dow Jones hit all-time highs since February, marking its fastest bear market recovery in 30 years.
Disappointing Retail Sales Data for October
by Zacks Equity Research
Disappointing Retail Sales Data for October.
Why Airline Space is Upbeat Despite Spike in US Coronavirus Cases
by Maharathi Basu
The positive update on Moderna's (MRNA) coronavirus vaccine candidate drives airline stocks like Delta (DAL), American Airlines (AAL), United Airlines (UAL) and Southwest Airlines (LUV) higher on Nov 16..
Economic Metrics Slimmer, Walmart (WMT) Beats Estimates
by Mark Vickery
All of today's reads are for the month of October: Retail Sales, Import and Export Price Indexes and Industrial Production and Capacity Utilization.
Moderna's (MRNA) Coronavirus Vaccine Progress Hurts Pfizer
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate seems to be more effective and its logistics less onerous than Pfizer and BioNTech's candidate.
Reasons to Bet on High Beta ETFs & Stocks
by Sweta Killa
The momentum was driven by a vaccine development, which is being viewed as "a beginning to the end" of the coronavirus pandemic, and the prospect of divided congress, which is considered favorable for the economy.
Stock Market News for Nov 17, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Monday buoyed by positive developments on coronavirus treatment front.
Energy Stocks Soar in Monday's Trading Session: Here's Why
by Nilanjan Choudhury
Energy was Monday's leading S&P sector performer with notable movers being TechnipFMC (FTI), Schlumberger (SLB), National Oilwell Varco (NOV) and Valero Energy (VLO).
Pfizer (PFE), BioNTech Fall After Moderna COVID-19 Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) stocks decline after Moderna COVID-19 vaccine candidate proves 94.5% effective and can be stored at standard refrigerator temperature.
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
Positive Vaccine Data Propels Bank Stocks: 5 Top-Ranked Picks
by Swayta Shah
Vaccine-related news from Moderna (MRNA) and Pfizer (PFE) will have positive impact on banks. We choose Triumph Bancorp (TBK), First Financial (FFIN), Flagstar Bancorp (FBC), Investors Bancorp (ISBC) & Meta Financial (CASH) for you to consider.
5 Value Stocks to Benefit From Positive Vaccine News
by Zacks Equity Research
Positive vaccine news will help cyclical stocks make a comeback, making it judicious to invest in names like Vista Outdoor (VSTO) and Malibu Boats (MBUU).
3 Stocks to Win Big as Race for Coronavirus Vaccine Heats Up
by Tirthankar Chakraborty
Coronavirus vaccine race is now at its peak following Moderna's (MRNA) 94.5% effective vaccine in Phase 3 trials. Pfizer (PFE) also bragged about the effectiveness of its vaccine to be more than 90%.
Leisure Stocks & ETFs Rally on Strong Vaccine Hopes
by Sanghamitra Saha
Hopes of a sooner-than-expected coronavirus vaccine launch led Wall Street to a record high on Nov 16 .
Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks
by Nalak Das
Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).
Small-Cap Value ETF (FYT) Hits a New 52-Week High
by Sanghamitra Saha
This small-cap value ETF has hit a new 52-week high. Are more gains in store?
Markets Begin Pricing In Post-Pandemic Reality
by Mark Vickery
This is the second consecutive Monday where excellent news on Covid-19 vaccine potential got the trading week off on the right foot.
Energy ETFs Jump on Coronavirus Vaccine News
by Zacks Equity Research
Energy stocks have benefited from vaccine optimism
Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.
Vaccine Data Propels Stocks: Global Week Ahead
by John Blank
Moderna said in a Phase 3 trial, which enrolled 30K patients, its vaccine demonstrated 94.5% efficacy. The trial included "many high-risk or elderly" people. Furthermore, their vaccine can be stored a temperatures a commercial freezer can likely supply, easing distribution concerns.
Positive Developments on COVID-19 Treatment Front
by Zacks Equity Research
Positive Developments on COVID-19 Treatment Front.